TScan Therapeutics

TScan Therapeutics

TCRX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -67.1% in FY2025

Gavin MacBeath, Ph.D. is the CEO of TScan Therapeutics and was paid $2.8M in FY2025 (Dec).

Pay$100 in the stock at the end of FY21 → $43
CEO pay is from each TScan Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Chrystal Louis, M.D., M.P.H.FY2024
  2. 2Gavin MacBeath, Ph.D.FY2025
  3. 3Jason A. AmelloFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

TScan Therapeutics paid its 2 named executives $4.1M in total in FY2025 (Dec). CEO Gavin MacBeath, Ph.D. was paid $2.8M of that.

Name
Gavin MacBeath, Ph.D.Chief Executive Officer and DirectorNot disclosed
Jason A. AmelloChief Financial Officer and TreasurerNot disclosedNot disclosed
Chrystal Louis, M.D., M.P.H.Chief Medical OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for TScan Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board1

See all
  • Barbara Klencke, M.D.Director · 2 yr on the boardIndependent—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 17, 2026FY2025
Annual report10-KMar 4, 2026FY2025
Proxy statementDEF 14AMay 14, 2025FY2024
Annual report10-KMar 5, 2025FY2024
Proxy statementDEF 14AApr 30, 2024FY2023
Annual report10-KMar 6, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data